Explore News By Topic

10/15/2019

Artificial Intelligence and Prostate Cancer Diagnosis

The field of artificial intelligence (AI) started in the 1950’s in the defense industry, and has evolved over the years. In the 2010s, new computer-based “deep-learning” methods were introduced that significantly accelerated the field. Physician-scientists are using this technology in the medical field to improve diagnostic methods. One such researcher... Read More

10/01/2019

Studying the Effects of ADT on Brain Function

Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer, and acts by blocking the production or action of testosterone and other male hormones that activate the androgen receptor (AR). Studies have suggested that ADT may affect cognition and has been associated with the development of Alzheimer’s disease and... Read More

09/18/2019

BREAKING NEWS: FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer

September 18, 2019 – Last night the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Apalutamide has previously received FDA-approval for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded the initial synthesis of apalutamide at UCLA... Read More

09/04/2019

The Prostate Cancer Foundation Made History by Lighting U.S. Landmarks “Blue” Across All 50 States to Illuminate Prostate Cancer Issue

LOS ANGELES, Calif., September 4, 2019 – For the first time in American history, U.S. landmarks in all 50 states (and the District of Columbia) were lit blue on September 3 to kick-off Prostate Cancer Awareness Month. The Prostate Cancer Foundation’s (PCF) “Light It Blue” campaign is a national effort... Read More

08/22/2019

The Prostate Cancer Foundation and the Movember Foundation Announce 2019 Challenge Award Winners

The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced three new Movember Foundation-PCF Challenge Awards. These are granted to teams at some of the world’s leading cancer research institutions. They will receive a total of $2.5 million to support cross-disciplinary pioneering research toward the goal of finding a... Read More

07/30/2019

FDA Approves Bayer’s Nubeqa® (darolutamide), a New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer

WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).  The FDA approval is based on the Phase III ARAMIS trial evaluating Nubeqa plus androgen deprivation... Read More

07/23/2019

Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine

Original Press Release Issued by: The Institute of Cancer Research, London Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports. An emerging class of drugs are made up of a radioactive particle that... Read More

06/26/2019

Newly defined cancer driver is Fast, Furious and Loud

Original Press Release Issued by: University of Michigan Medicine ANN ARBOR, Michigan — The Fast and the Furious movie franchise meets the Fast N’ Loud television series to define an oncogene that drives 35% of prostate cancers. A new study from researchers at the University of Michigan Rogel Cancer Center... Read More

06/12/2019

New Class of Life-Extending Drugs for Men with Metastatic Hormone-Sensitive Prostate Cancer

At the 2019 American Society of Clinical Oncology (ACSO) Annual Meeting, results presented by two PCF-funded investigators from pivotal phase 3 clinical trials will likely lead to approval of a new class of life-extending treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC). mHSPC refers to men whose prostate... Read More

05/30/2019

THE PROSTATE CANCER FOUNDATION AND MAJOR LEAGUE BASEBALL KICK OFF 24th ANNUAL HOME RUN CHALLENGE ON JUNE 1st

One in 9 U.S. men will be diagnosed with prostate cancer which is equivalent to at least one player on a baseball team One man dies from prostate cancer every 17 minutes which is roughly equivalent to one player per inning More than 31,000 men will die from prostate cancer... Read More